A novel metered-dose 2% testosterone gel treatment for male hypogonadism

Rommerts, 1998, Testosterone: an overview of biosynthesis, transport, metabolism and nongenomic actions Mahmoud, 2006, Mechanisms of disease: late-onset hypogonadism, Nat Clin Pract Urol, 3, 430, 10.1038/ncpuro0560 Nieschlag, 2005, Investigation, treatment and monitoring of late-onset hypogonadism in males. ISA, ISSAM, and EAU recommendations, Eur Urol, 48, 1, 10.1016/j.eururo.2005.04.027 Orwoll, 2006, Endogenous testosterone levels, physical performance, and fall risk in older men, Arch Intern Med, 166, 2124, 10.1001/archinte.166.19.2124 Shores, 2006, Low serum testosterone and mortality in male veterans, Arch Intern Med, 166, 1660, 10.1001/archinte.166.15.1660 Zitzmann, 2001, Testosterone levels in healthy men and the relation to behavioural and physical characteristics: facts and constructs, Eur J Endocrinol, 144, 183, 10.1530/eje.0.1440183 Araujo, 2004, Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study, J Clin Endocrinol Metab, 89, 5920, 10.1210/jc.2003-031719 Gould, 2006, Hypoandrogen–metabolic syndrome: a significant issue for men's health, BJU Int, 98, 494, 10.1111/j.1464-410X.2006.06291.x Mulligan, 2006, Prevalence of hypogonadism in males aged at least 45 years: the HIM study, Int J Clin Pract, 60, 762, 10.1111/j.1742-1241.2006.00992.x Bagatell, 1996, Androgens in men – uses and abuses, N Engl J Med, 334, 707, 10.1056/NEJM199603143341107 Matsumoto, 1994, Hormonal therapy of male hypogonadism, Endocrinol Metab Clin North Am, 23, 857, 10.1016/S0889-8529(18)30072-0 Meinhardt, 1999, Comparative tolerability and efficacy of treatments for impotence, Drug Saf, 20, 133, 10.2165/00002018-199920020-00004 Lund, 1999, Testosterone and andropause: the feasibility of testosterone replacement therapy in elderly men, Pharmacotherapy, 19, 951, 10.1592/phco.19.11.951.31574 Vermeulen, 2001, Androgen replacement therapy in the aging male – a critical evaluation, J Clin Endocrinol Metab, 86, 2380, 10.1210/jc.86.6.2380 Handelsman, 2004, Androgen deficiency and replacement therapy in men, MJA Practice Essentials, 180, 529 Snyder, 1980, Treatment of male hypogonadism with testosterone enanthate, J Clin Endocrinol Metab, 51, 1335, 10.1210/jcem-51-6-1335 Findlay, 1989, Treatment of primary hypogonadism in men by the transdermal administration of testosterone, J Clin Endocrinol Metab, 68, 369, 10.1210/jcem-68-2-369 Jordan, 1998, Comparison of the skin irritation potential of two testosterone transdermal systems: an investigational system and a marketed product, Clin Ther, 20, 80, 10.1016/S0149-2918(98)80036-2 Nieschlag, 2004, Testosterone replacement therapy: current trends and future directions, Hum Reprod Update, 10, 409, 10.1093/humupd/dmh035 Swerdloff, 2000, Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men, J Clin Endocrinol Metab, 85, 4500, 10.1210/jc.85.12.4500 Tostran. Summary of Product Characteristics. Galashiels: ProStrakan Ltd; 2006. Available at: http://emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp?documentid=19702. Dumas C. Flexibility in dosing with a new topical 2% testosterone gel. Poster presented at the 25th Scandinavian Meeting of Urology, Goteborg; 2005. Testogel. Summary of Product Characteristics. Berlin: Bayer Schering Pharma AG; 2006. Available at: http://emc.medicines.org.uk/emc/assets/c/html/DisplayDoc.asp?DocumentID=12391. Testim. Summary of Product Characteristics. Slough: Ipsen: 2004. Available at: http://emc.medicines.org.uk/emc/assets/c/html/displayDocPrinterFriendly.asp?documentid=15906. 1997 World Medical Association, 2006 2004